National, Regional, State, and Selected Local Area Vaccination Coverage Among Adolescents Aged 13-17 Years--United States, 2014

Abstract

Routine immunization is recommended for adolescents aged 11-12 years by the Advisory Committee on Immunization Practices (ACIP) for protection against diseases including pertussis, meningococcal disease, and human papillomavirus (HPV)-associated cancers. To assess vaccination coverage among adolescents, CDC analyzed data collected regarding 20,827 adolescents through the 2014 National Immunization Survey-Teen (NIS-Teen). From 2013 to 2014, coverage among adolescents aged 13-17 years increased for all routinely recommended vaccines: from 84.7% to 87.6% for ≥1 tetanus-diphtheria-acellular pertussis (Tdap) vaccine dose, from 76.6% to 79.3% for ≥1 meningococcal conjugate (MenACWY) vaccine dose, from 56.7% to 60.0% and from 33.6% to 41.7% for ≥1 HPV vaccine dose among females and males, respectively.† Coverage differed by state and local area. Despite overall progress in vaccination coverage among adolescents, HPV vaccination coverage continues to lag behind Tdap and MenACWY coverage at state and national levels. Seven public health jurisdictions achieved significant increases in ≥1- or ≥3-dose HPV vaccination coverage among females in 2014, demonstrating that substantial improvement in HPV vaccination coverage is feasible.

Figures

FIGURE 1

Estimated vaccination coverage with selected vaccines and doses among adolescents aged 13–17 years, by survey year — National Immunization Survey–Teen, United States, 2006–2014 Abbreviations: Tdap = tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis; MenACWY = meningococcal conjugate; HPV = human papillomavirus; ACIP = Advisory Committee on Immunization Practices; APD = adequate provider data. * =1 dose Tdap vaccine at or after age 10 years. † =1 dose MenACWY or meningococcal-unknown type vaccine. § =2 doses MenACWY or meningococcal-unknown type vaccine, calculated only among adolescents aged 17 years at time of interview. Does not include adolescents who received their first and only dose of MenACWY at age 16 years or later. ¶HPV vaccine, either bivalent (2vHPV) or quadrivalent (4vHPV), among females. ACIP recommends 2vHPV, 4vHPV, or nine-valent (9vHPV) vaccine for females. Although the 9vHPV vaccine was licensed in December 2014 and recommended by ACIP in February 2015, it was not distributed until 2015 and thus was not administered to adolescents in 2014. ** HPV vaccine, either 2vHPV or 4vHPV, among males. ACIP recommends the 4vHPV or 9vHPV vaccines for males; however, some males might have received the 2vHPV vaccine. Although the 9vHPV vaccine was licensed in December 2014 and recommended by ACIP in February 2015, it was not distributed until 2015 and thus was not administered to adolescents in 2014. †† NIS-Teen implemented a revised APD definition in 2014 and retrospectively applied the revised APD definition to 2013 data. Estimates using different APD definitions might not be directly comparable.

FIGURE 2

Estimated vaccination coverage with ≥1 dose of human papillomavirus (HPV) vaccine* among females aged 13–17 years† — United States, National Immunization Survey–Teen, 2014 * HPV vaccine, either quadrivalent or bivalent. † Includes females (N = 10,084) born during the period January 1996–February 2002.

FIGURE 3

Estimated vaccination coverage with ≥1 dose of human papillomavirus (HPV) vaccine* among males aged 13–17 years† — United States, National Immunization Survey–Teen, 2014 * HPV vaccine, either quadrivalent or bivalent. † Includes males (N = 10,743) born during the period January 1996–February 2002.